Citi's $35bn Booking Blunder Exposes Banking's Control Gap
Published on 22 November 2026
Read article
Listen to article
6:04Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
When a man who measures his investments in decades, not quarters, makes a multi-billion-dollar move, I tend to sit up and put the kettle on. Warren Buffett, the nonagenarian Sage of Omaha, has just ploughed a cool $2.1 billion into UnitedHealth Group. To me, this isn't just another line item in Berkshire Hathaway’s portfolio. It’s a flare sent up over a sector many had written off as a political football, a signal that there might be serious value hiding in plain sight.
Let’s be honest, healthcare investing hasn’t exactly been a thrilling ride of late. It’s a minefield of regulatory jargon, political grandstanding, and endless debates about costs. After Buffett’s own much-hyped healthcare venture with Amazon and JPMorgan fizzled out a few years ago, you could have forgiven him for steering well clear. And yet, here he is, back again, and he’s not paddling in the shallow end.
This move feels different. It’s a classic Buffett play. He’s wading in when others are hesitant, looking past the short-term noise to the fundamental, unshakeable truth of the industry. What is that truth? Well, people get old, and people get sick. It’s not a cheerful thought, but it’s a brutally reliable business model. In a world obsessed with the next flashy tech disruptor, Buffett is reminding us that some of the best opportunities are found in the boring, essential services that underpin society.
So, why UnitedHealth? It’s America’s largest health insurer, a behemoth with its tentacles in everything from insurance plans to pharmacy benefits. In Buffett-speak, it has a formidable "moat". The barriers to entry are colossal. You can’t just whip up a health insurance giant in your garage. This creates a predictable, cash-generative business that can weather economic storms far better than most.
When inflation is biting and recession fears are swirling, this kind of defensive quality is worth its weight in gold. People will cancel their streaming subscriptions long before they cancel their health insurance. This isn't about chasing explosive growth, it's about finding a sturdy ship in choppy waters. And when the world’s most famous value investor endorses that ship, other big money managers tend to take notice. His bet could easily trigger a re-evaluation of the entire sector, pulling other well-run insurers like Humana and Elevance Health along for the ride. It’s this broader trend that makes a strategy like Following Buffett's Healthcare Bet so compelling to me.
Now, let’s not get carried away. This is not a risk-free punt. The healthcare industry is perpetually in the crosshairs of politicians looking for an easy win. A single piece of legislation could change the game overnight, and the pressure on drug pricing and insurance practices is relentless. Anyone diving in needs to understand that regulatory risk is part of the deal. Buffett knows this, of course. His investment isn't a bet that these problems will disappear, it's a calculated judgement that a quality company like UnitedHealth is well-equipped to navigate them and is currently priced attractively enough to compensate for those risks. He’s looking at the long-term demographic tailwind of an ageing population and seeing a force more powerful than any short-term political squabble.
View the full Basket:Following Buffett's Healthcare Bet
All investments carry risk and you may lose money.
View the full Basket:Following Buffett's Healthcare Bet
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 22 November 2026
Read article
Published on 22 November 2026
Read article
Published on 21 November 2026
Read article
Published on 21 November 2026
Read article
Published on 19 November 2026
Read article